ALNYLAM PHARMACEUTICALS ($ALNY) is expected to release its quarterly earnings data on Monday, January 12th after market close, per Finnhub. Analysts are expecting revenue of $1,196,699,190 and earnings of $1.25 per share.
You can see Quiver Quantitative's $ALNY stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ALNYLAM PHARMACEUTICALS Insider Trading Activity
ALNYLAM PHARMACEUTICALS insiders have traded $ALNY stock on the open market 176 times in the past 6 months. Of those trades, 0 have been purchases and 176 have been sales.
Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:
- YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 40 sales selling 41,553 shares for an estimated $18,810,433.
- DENNIS A AUSIELLO has made 0 purchases and 11 sales selling 31,448 shares for an estimated $13,729,535.
- COLLEEN F REITAN has made 0 purchases and 16 sales selling 18,000 shares for an estimated $8,416,729.
- KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 31 sales selling 15,965 shares for an estimated $7,220,199.
- MICHAEL W BONNEY sold 11,250 shares for an estimated $5,062,500
- PUSHKAL GARG (EVP Chief R&D) has made 0 purchases and 31 sales selling 8,810 shares for an estimated $3,991,807.
- TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 26 sales selling 6,275 shares for an estimated $2,825,534.
- JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 20 sales selling 6,095 shares for an estimated $2,758,010.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ALNYLAM PHARMACEUTICALS Revenue
ALNYLAM PHARMACEUTICALS had revenues of $1.2B in Q3 2025. This is an increase of 149.35% from the same period in the prior year.
You can track ALNY financials on Quiver Quantitative's ALNY stock page.
ALNYLAM PHARMACEUTICALS Hedge Fund Activity
We have seen 480 institutional investors add shares of ALNYLAM PHARMACEUTICALS stock to their portfolio, and 283 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- REGENERON PHARMACEUTICALS, INC. removed 3,052,142 shares (-68.7%) from their portfolio in Q3 2025, for an estimated $1,391,776,752
- JPMORGAN CHASE & CO added 2,481,762 shares (+120.4%) to their portfolio in Q3 2025, for an estimated $1,131,683,472
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 2,107,295 shares (-49.2%) from their portfolio in Q3 2025, for an estimated $960,926,520
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,344,712 shares (-42.8%) from their portfolio in Q3 2025, for an estimated $613,188,672
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 1,185,909 shares (+698.8%) to their portfolio in Q3 2025, for an estimated $540,774,504
- WINSLOW CAPITAL MANAGEMENT, LLC removed 1,176,104 shares (-99.9%) from their portfolio in Q3 2025, for an estimated $536,303,424
- FMR LLC added 961,104 shares (+6.1%) to their portfolio in Q3 2025, for an estimated $438,263,424
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ALNYLAM PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 16 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 01/08/2026
- Stifel issued a "Buy" rating on 12/11/2025
- Barclays issued a "Overweight" rating on 10/31/2025
- Piper Sandler issued a "Overweight" rating on 10/31/2025
- Jefferies issued a "Buy" rating on 10/30/2025
- JP Morgan issued a "Overweight" rating on 10/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 10/10/2025
To track analyst ratings and price targets for ALNYLAM PHARMACEUTICALS, check out Quiver Quantitative's $ALNY forecast page.
ALNYLAM PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $ALNY recently. We have seen 25 analysts offer price targets for $ALNY in the last 6 months, with a median target of $490.0.
Here are some recent targets:
- Danielle Brill from Truist Securities set a target price of $530.0 on 01/08/2026
- Mani Foroohar from Leerink Partners set a target price of $351.0 on 12/15/2025
- Paul Matteis from Stifel set a target price of $508.0 on 12/11/2025
- Derek Archila from Wells Fargo set a target price of $479.0 on 11/11/2025
- Gena Wang from Barclays set a target price of $527.0 on 10/31/2025
- Edward Tenthoff from Piper Sandler set a target price of $489.0 on 10/31/2025
- Maury Raycroft from Jefferies set a target price of $549.0 on 10/30/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
